# OnCo record essential-thrombocythaemia (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/essential-thrombocythaemia/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "essential-thrombocythaemia" ;
  schema:name "Essential thrombocythaemia (ET)"@en ;
  schema:alternateName "Essential thrombocythemia"@en, "ET"@en, "Primary thrombocythaemia"@en, "Essential thrombocytosis"@en ;
  schema:description "Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve."@en ;
  schema:url <https://onco.cc/cancers/essential-thrombocythaemia/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Essential_thrombocythemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Essential_thrombocythemia>, <https://www.mpnresearchfoundation.org/essential-thrombocythemia/> ;
  onco:tag "essential-thrombocythaemia", "mpn" ;
  onco:related <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/primary-myelofibrosis/> ;
  onco:terms <https://onco.cc/terms/ipset-thrombosis/>, <https://onco.cc/terms/mpn-driver-mutations/> ;
  onco:pipeline <https://onco.cc/drugs/bomedemstat/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/> ;
  onco:standardOfCare <https://onco.cc/targets/jak2/>, <https://onco.cc/terms/jak2-v617f/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/drugs/aspirin/>, <https://onco.cc/terms/erythromelalgia/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/trials/pt-1/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/drugs/anagrelide/>, <https://onco.cc/drugs/anagrelide/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/trials/majic-et/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/terms/post-pv-myelofibrosis/>, <https://onco.cc/drugs/ruxolitinib/> .